Effect of Synthetic Truncated Apolipoprotein C-I Peptide on Plasma
Lipoprotein Cholesterol in Nonhuman Primates by Kushwaha, Rampratap S. et al.
© 2004 Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology • 2004:4 (2004) 177–184 • PII. S1110724304311010 • http://jbb.hindawi.com
RESEARCH ARTICLE
Effect of Synthetic Truncated Apolipoprotein
C-I Peptide on Plasma Lipoprotein Cholesterol
in Nonhuman Primates
Rampratap S. Kushwaha,1∗ Henry C. McGill Jr,1 and Frederick H. Hausheer2
1Department of Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, TX 78245-0549, USA
2BioNumerik Pharmaceuticals, Inc, San Antonio, TX 78229, USA
Received 24 November 2003; revised 26 May 2004; accepted 2 June 2004
The present studies were conducted to determine whether a synthetic truncated apoC-I peptide that inhibits CETP activity in ba-
boons would raise plasma HDL cholesterol levels in nonhuman primates with low HDL levels. We used 2 cynomolgus monkeys and
3 baboons fed a cholesterol- and fat-enriched diet. In cynomolgus monkeys, we injected synthetic truncated apoC-I inhibitor peptide
at a dose of 20mg/kg and, in baboons, at doses of 10, 15, and 20mg/kg at weekly intervals. Blood samples were collected 3 times a
week and VLDL + LDL and HDL cholesterol concentrations were measured. In cynomolgus monkeys, administration of the inhibitor
peptide caused a rapid decrease in VLDL + LDL cholesterol concentrations (30%–60%) and an increase in HDL cholesterol con-
centrations (10%–20%). VLDL + LDL cholesterol concentrations returned to baseline levels in approximately 15days. In baboons,
administration of the synthetic inhibitor peptide caused a decrease in VLDL + LDL cholesterol (20%–60%) and an increase in HDL
cholesterol (10%–20%). VLDL + LDL cholesterol returned to baseline levels by day 21, whereas HDL cholesterol concentrations
remained elevated for up to 26days. ApoA-I concentrations increased, whereas apoE and triglyceride concentrations decreased. Sub-
cutaneous and intravenous administrations of the inhibitor peptide had similar eﬀects on LDL and HDL cholesterol concentrations.
There was no change in body weight, food consumption, or plasma IgG levels of any baboon during the study. These studies suggest
that the truncated apoC-I peptide can be used to raise HDL in humans.
INTRODUCTION
Plasma high-density lipoproteins (HDL), which
are negatively correlated with the extent of coronary
atherosclerosis and the risk of coronary heart disease
(CHD) [1, 2, 3], vary considerably among experimental
animals and humans [4, 5, 6]. A number of genetic and
dietary factors aﬀect plasma HDL cholesterol levels in hu-
mansandnonhumanprimates[7,8,9].Selectivebreeding
has produced baboons with high and low HDL levels in
response to a cholesterol- and fat-enriched diet [5]. The
baboons of high-HDL families induce large HDL parti-
cles when challenged with a high-cholesterol and high-fat
(HCHF) diet [6]. Our metabolic studies suggested that
baboons with high HDL have a slower cholesteryl es-
ter transfer from HDL to very low-density lipoproteins
(VLDL) and low-density lipoproteins (LDL) on both the
low-cholesterol low-fat basal diet and the HCHF diet [6].
The slower cholesteryl ester transfer from HDL to lower-
density lipoproteins was due to an inhibitor of cholesterol
ester transfer protein (CETP) rather than a lack of CETP
mass [6]. The CETP inhibitor peptide was identiﬁed as
an N-terminal fragment of apolipoprotein (apo) C-I [10]
with a molecular weight of 4kd. Both the natural and the
synthetic CETP inhibitor peptide inhibited CETP activ-
ity in the plasma of low-HDL baboons [10]. An antibody
against the CETP synthetic peptide increased cholesteryl
ester transfer from HDL of high-HDL baboons, whereas
the antibody to CETP decreased the cholesteryl ester
transfer from HDL of both high- and low-HDL baboons
[10].Thepresentstudieswereconductedtodeterminethe
eﬀect of synthetic truncated apoC-I peptide on plasma
VLDL + LDL and HDL cholesterol concentrations in ba-
boons and cynomolgus monkeys consuming the HCHF
diet. We also compared the eﬀect of the route of admin-
istration of the peptide and the eﬀect of the peptide on
body weight, food consumption, and immune response.
MATERIALS AND METHODS
Animalsanddiets
Three adult male baboons (12–18kg) and two adult
male cynomolgus monkeys (6–8kg) were used for these
studies. Baboons selected for these studies did not in-
duce large HDL particles in their plasma on the HCHF
diet. Both baboons and cynomolgus monkeys consumed
the HCHF diet for at least 3 months prior to the start of
the experiment and continued consuming the HCHF diet
throughout the experimental period. The diet provided178 Rampratap S. Kushwaha et al 2004:4 (2004)
40% of total calories from lard and contained cholesterol
at 1.7mg/kcal as described previously [5, 6]. We used an-
other 6 baboons for the measurement of inhibition of
cholesteryl ester transfer from HDL to VLDL + LDL in
vitro.
MeasurementofCETPinhibitoractivity
oftruncatedapoC-Ipeptide
The eﬀect of truncated apoC-I peptide on mass trans-
fer of cholesteryl ester from HDL to VLDL+LDL was
measured by using a whole plasma system [11]o rar e -
constituted assay system described by us [6]. For as-
says described here, we used a reconstituted system.
Blood (25mL each) was obtained from a donor and
HDL and VLDL+LDL were isolated by ultracentrifu-
gation [6]. HDL was labeled with [3H]-cholesteryl es-
ter and incubated (10µg HDL cholesterol) with 50 to
100µg of VLDL+LDL cholesterol in presence of CETP
and 2mM dithio-bis-dinitrobenzoic acid (DTNB) to in-
hibit lecithin-cholesterol acyltransferase [6]. CETP was
isolatedfromtheplasmaof6donorsasthelipoproteinde-
ﬁcient fraction d>1.021g/mL. Incubations were carried
o u ta t4 ◦Ca n d3 7 ◦C with or without the apoC-I trun-
cated peptide (25µM). The VLDL+LDL was precipitated
with 0.1 volume of heparin-manganese chloride to give a
ﬁnalconcentrationofmanganesechlorideat0.092 Mand
heparinat1.3 mg/mL[11].RadioactivityinHDLfraction
was measured by scintillation spectrometry (Beckman In-
struments, Palo Alto, Calif). The diﬀerence in cholesteryl
ester transfer between 4◦Ca n d3 7 ◦Cw a sd u et oC E T P
activity [6]. The cholesteryl transfer in assay mixture in-
cubated with the truncated peptide was expressed as the
percentof transferin assay mixture incubated without the
truncated apoC-I peptide for the same CETP.
Studiesincynomolgusmonkeys
Cynomolgus monkeys were given an intravenous in-
jection of the truncated apoC-I peptide at 20mg/kg body
weight. Cynomolgus monkeys were implanted with a
jugular catheter and maintained on a tether system to
facilitate blood drawing and infusion of the synthetic
apoC-I peptide. After a steady baseline, the peptide was
injected and blood was drawn three times a week.
Studiesinbaboons
We studied two modes (subcutaneous and intra-
venous) of administration of truncated apoC-I peptide
in baboons. Baboons were also implanted with a jugular
catheter and maintained on a tether system to facilitate
blood drawing and infusion of the peptide. Baboons were
injected with sterile saline as placebo and cholesterol con-
centrations of plasma lipoproteins were measured. After a
steadybaseline,thetruncatedapoC-Ipeptidewasinjected
at weekly intervals at 10, 15, and 20mg/kg body weight.
One dose of radiolabeled (tritium) truncatedapoC-I pep-
tide was also injected during each study. Blood samples
were drawn three times a week. Food consumption, body
weight, and total IgG levels (only one study) were mea-
sured.
SynthesisoftruncatedapoC-Ipeptide
The 38 amino acid N-terminal fragment of apoC-I
peptide based on human sequences [12] was synthesized
at the Microchemical Facility of the Emory University
School of Medicine on a contract basis. The baboon pep-
tide has 8 substitutions in this region compared to the
human sequence. These substitutions do not change the
hydrophobic nature of the peptide. The peptide (both
nonradioactive and radioactive) was synthesized by solid-
phase synthesis using the tBoc/benzyl protection strategy.
The peptide was puriﬁed by reversed-phase HPLC and
was received in freeze-dried form. The purity and struc-
tural integrity of the preparation was documented by mi-
crobore reversed-phase HPLC and by electrospray ion-
ization tandem mass spectrometry (communication by
Dr John Pohl, Director of Microchemical Facility, Emory
University, Atlanta, Ga).
PreparationoftruncatedapoC-Ipeptide
For subcutaneous injections, the truncated apoC-I
peptidewasdissolvedinsterileDMSOandthendilutedto
a concentration of 200mg/mL with sterile saline and the
ﬁnal concentration of DMSO was 5%. The solution was
f r o z e na n dt h a w e d1 2t i m e sa n ds t o r e da t−20◦Cp r i o r
to use. A volume of 0.5t o1 .5mL was injected subcuta-
neously. For intravenous injections, the appropriate dose
of peptide for each animal was dissolved in 1mL DMSO,
frozen and thawed 10 times, and diluted with 19mL ster-
ile saline. The CETP inhibitor solution was again frozen
at −20◦C prior to use. A volume of 20mL was infused in-
travenously over 2hours.
Bloodsamplingandseparation
ofplasmalipoproteins
After a fast of approximately 15hours, blood (2mL)
wasdrawnbyajugularcatheterfrombaboonsmaintained
onatethersystem.Bloodwascentrifugedinarefrigerated
low-speed centrifuge (Beckman Instruments, Palo Alto,
Calif) to obtain plasma. Lipoproteins were separated by
density gradient ultracentrifugation using SW 41 Ti ro-
t o ri naB e c k m a nu l t r a c e n t r i f u g eM o d e l8 - 7 0o rL 8 - 7 0 M
(Beckman Instruments) as described previously in [13].
Fractions were pooled on the basis of their densities mea-
sured by refractive index [13]. Densities of pooled frac-
tions corresponded to VLDL + LDL (d>1.045g/mL) and
HDL (d = 1.45 to 1.21g/mL). Plasma and lipoprotein
cholesterol concentrations were measured every other day
for 28days.
Plasmaandlipoproteincholesterol,triglycerides,
andtotalIgGmeasurements
Cholesterolconcentrationsinplasmaandlipoproteins
and triglyceride concentrations in plasma were measured
by an enzymatic method using a kit from Wako Pure2004:4 (2004) CETP Inhibitor Peptide and Plasma HDL 179
Chemical Industries (Richmond). Total plasma IgG was
measuredbyprecipitationwithsaturatedammoniumsul-
fate. The values of IgG are expressed as microgram per
deciliter.
Measurementofplasmaapolipoproteins
Plasma apoA-I and apoE in baboon plasma and apoB
in cynomolgus monkey plasma were measured by the
electroimmunoassay method as described by Mott et al
[14]. The antisera used for these assays were purchased
commercially (Boehringer Mannheim, Indianapolis, Ind)
and were monospeciﬁc.
Measurementsofradioactivityintruncated
apoC-Ipeptideinplasma
A small sample of plasma (50–100µL) was counted in
a liquid scintillation counter to measure the radioactivity
a n dw a sp l o t t e da sap e r c e n to fr a d i o a c t i v i t yr e c o v e r e di n
plasma at day 2.
Dataanalysis
The data in the ﬁgures have been presented as
mean±SE. The values for lipoprotein cholesterol and
apolipoprotein concentrations were compared with the
values at day 0 (baseline value) using analysis of variance.
The signiﬁcance was set at P<. 05. The half-life of the
peptide was calculated by plotting data on a log scale. The
data were log linear.
T h ep r o t o c o lo ft h i ss t u d yw a sa p p r o v e db yt h e
Institutional Animal Care and Use Committee of the
Southwest Foundation for Biomedical Research, which is
accredited by the American Association for Accreditation
of Laboratory Animal Care and is registered with the US
Department of Agriculture.
RESULTS
Effectoftruncatedpeptideoncholesterylester
transferfromHDLtoVLDL+LDLinbaboonplasma
We measured the mass transfer of cholesteryl ester
from HDL to VLDL + LDL in vitro in presence or ab-
sence (control) of truncated apoC-I peptide. As presented
in Figure 1, the addition of truncated apoC-I peptide in
the plasma considerably decreased (21% to 53% of con-
trol) cholesteryl ester transfer from HDL to VLDL + LDL.
EffectoftruncatedapoC-Ipeptideonplasma
lipoproteinsincynomolgusmonkeys
Plasma VLDL + LDL cholesterol concentrations for
two cynomolgus monkeys used for these studies were
569and671mg/dL.Thehypercholesterolemiawasmainly
due to the increased cholesterol in VLDL + LDL (greater
than 90% of total plasma cholesterol). Plasma HDL
cholesterol concentration (64 and 61mg/dL for two mon-
keys) was very low (less than 10% of total plasma
cholesterol). After injection of the truncated apoC-I pep-
tide in cynomolgus monkeys, there was a rapid drop
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Figure 1. Eﬀect of truncated apoC-I peptide on the mass trans-
fer of cholesteryl ester from HDL to VLDL + LDL in reconsti-
tute assays (n = 6). The cholesteryl ester transfer in the plasma
was measured by adding the truncated apoC-I peptide at a con-
centration of 25µM, as described in “methods.” The decrease
in cholesteryl ester transfer in plasma added with the truncated
peptide (peptide) has been expressed as the percent of transfer
in the plasma without the truncated peptide (control).
in the plasma VLDL + LDL cholesterol concentration
(Figure 2). The maximum decrease in plasma and VLDL
+ LDL cholesterol occurred at day 7 in both animals
and, at this point, there was a 26.5 ± 4.5% decrease in
plasma LDL cholesterol levels (P<. 05). The values for
VLDL + LDL cholesterol levels were also signiﬁcantly
lower (P<. 05) on days 3, 7, 11, and 14 than the base-
line (day 0) VLDL + LDL cholesterol levels. After day
7, the VLDL + LDL cholesterol started to go up and, at
day 21, the levels returned to baseline values. The HDL
cholesterol concentrations increased at day 4 (10%–20%)
and remained elevated until day 7, after which there was
a slight drop. There was considerable variability in HDL
cholesterol concentrations in both cynomolgus monkeys
and therefore, these values were not signiﬁcantly diﬀerent
from the baseline values (day 0 values).
Baseline values for plasma apoB in two cynomolgus
monkeys were 300 and 254mg/dL. After the injection of
the truncated apoC-I peptide, apoB decreased rapidly as
did VLDL + LDL cholesterol; the maximum decrease oc-
curred on day 7 (Figure 3). After day 7, the apoB began to
increase; like VLDL + LDL cholesterol, the plasma apoB
concentration returned to baseline levels by day 21. The
apoB concentrations were lower on days 7, 9, and 11 than
the baseline apoB concentrations.
EffectofsubcutaneousinjectionsoftruncatedapoC-I
peptideonplasmalipoproteinsinbaboons
Compared with cynomolgus monkeys, baboons had
moderate hyperlipidemia (VLDL + LDL cholesterol,
148.33±36.55;HDLcholesterol,104.67±7.33;andplasma180 Rampratap S. Kushwaha et al 2004:4 (2004)
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Figure 2.AveragepercentchangeinplasmaHDL(∆)andVLDL
+L D L( ∇) cholesterol concentrations in cynomolgus mon-
keys after a single injection of the truncated apoC-I peptide at
20mg/kg on day 0 (arrow). Monkeys were fed the HCHF diet.
Values are expressed as mean±SE, n = 2. Values signiﬁcantly
diﬀerent from those at day 0 are marked by an asterisk (P<. 05).
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Figure 3. Average percent changes in plasma apoB concentra-
tions in cynomolgus monkeys (∇) after a single injection of the
truncated apoC-I peptide at 20mg/kg on day 0 (arrow). Mon-
keys were fed the HCHF diet. Values are expressed as mean±SE,
n = 2. Values signiﬁcantly diﬀerent from those at day 0 are
marked by an asterisk (P<. 05).
triglycerides, 45.33 ± 3.48; mg/dL, mean±SE). Figure 4
presents average percent changes in plasma lipoprotein
cholesterol concentrations in 3 baboons injected with
CETP inhibitor peptide subcutaneously. After the ﬁrst
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Figure 4. Average percent change in HDL (∆)a n dV L D L
+L D L( ∇) cholesterol concentrations in baboons after sub-
cutaneous injections of the truncated apoC-I peptide at 10,
15, and 20mg/kg on days 0, 7, and 14, respectively (arrows).
The baboons were fed the HCHF diet. Values are expressed as
mean±SE, n = 3. Values signiﬁcantly diﬀerent from those at day
0 are marked by an asterisk (P<. 05).
injection of truncated apoC-I peptide (10mg/kg), the
HDL cholesterol concentration started to go up, whereas
the VLDL + LDL cholesterol concentration started to go
down. After the second injection (15mg/kg) on day 7,
the HDL and VLDL + LDL cholesterol concentrations
remained the same. However, after the third injection
(20mg/kg) on day 14, the VLDL + LDL cholesterol went
down further but, after day 21, it started to rise and re-
turned to baseline values on day 28. On the other hand,
after the third injection, the HDL cholesterol went up and
stayed up during the rest of the experimental period. The
maximum decrease in VLDL + LDL cholesterol was 20%
onday19,whereasthemaximumincreaseinHDLcholes-
terolwas20%onday23.MostofthevaluesofplasmaLDL
and HDL cholesterol concentrations after the treatment
with truncated apoC-I peptide were signiﬁcantly diﬀerent
from values at the baseline.
EffectofintravenousinjectionsoftruncatedapoC-I
peptideonplasmalipoproteinsinbaboons
Figure 5 presents the average changes in plasma
lipoprotein cholesterol in 3 baboons injected with trun-
cated apoC-I peptide intravenously. As in the case of sub-
cutaneous injections, after the ﬁrst injection (10mg/kg),
there was a rapid increase in HDL cholesterol and a rapid
decrease in VLDL + LDL cholesterol. After the second in-
jection (15mg/kg), there was no further change in HDL
cholesterol concentration; however, there was a further
decrease in VLDL + LDL cholesterol concentration. Af-
ter day 10, the VLDL + LDL cholesterol began to rise, but2004:4 (2004) CETP Inhibitor Peptide and Plasma HDL 181
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Figure 5. Average percent change in HDL (∆)a n dV L D L+L D L
(∇) cholesterol concentrations in baboons after intravenous in-
jections of the truncated apoC-I peptide at 10, 15, and 20mg/kg
on days 0, 7, and 14, respectively (arrows). The baboons were
fed the HCHF diet. Values are expressed as mean±SE, n = 3.
Values signiﬁcantly diﬀerent from those at day 0 are marked by
an asterisk (P<. 05).
after the third injection on day 14 (20mg/kg), the VLDL
+ LDL cholesterol decreased further but there was very
little change in the HDL cholesterol concentration. After
day 20, VLDL + LDL cholesterol began decreasing till it
reached baseline values by day 25. However, as with the
subcutaneous injections, the HDL cholesterol remained
elevated until day 28. The maximum decrease in VLDL
+ LDL cholesterol concentration was 40%, whereas the
maximum increase in HDL cholesterol concentration was
20% (P<. 05).
As presented in Figure 6, there was an increase in
apoA-I in plasma after the injection of truncated apoC-I
peptide.ThebaselinevaluesforapoA-Iwere133.67±1.45
(mean±SE, n = 3). After the initial injection, there was
a small increase in apoA-I levels; however, after the sec-
ond and third injections, there was a rapid and larger in-
crease in apoA-I in the plasma. There was a 20% increase
inapoA-Iafterthesecondinjectionbutthelevelsreturned
to baseline on day 28. Values of ApoA-I concentration af-
ter the treatment with apoC-I truncated peptide were sig-
niﬁcantly higher than the baseline values on days 10, 15,
17, and 23 (P<. 05).
In contrast to plasma apoA-I levels, plasma apoE lev-
els decreased in response to each injection of the peptide
intravenously (Figure 6). The maximum decrease in apoE
was 25% on day 10. The baseline values for apoE were
4.37±0.62 (mean±SE, n = 3). Values of apoE concentra-
tion were signiﬁcantly lower than the baseline values on
days 2, 8, 10, 19, 22, and 26 (P<. 05).
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Figure 6. Average percent change in apolipoprotein A-I (∇)
and apolipoprotein E (∆) concentrations in baboons after in-
travenous injections of the truncated apoC-I peptide at 10,
15, and 20mg/kg on days 0, 7, and 14, respectively (arrows).
The baboons were fed the HCHF diet. Values are expressed as
mean±SE, n = 3. Values signiﬁcantly diﬀerent from those at day
0 are marked by an asterisk (P<. 05).
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Figure 7. Average percent change in plasma triglyceride con-
centrations in baboons after intravenous injections of the trun-
cated apoC-I peptide at 10, 15, and 20mg/kg at days 0, 7, and
14, respectively (arrows). The baboons were fed the HCHF diet.
Values are expressed as mean±SE, n = 3. Values signiﬁcantly
diﬀerent from those at day 0 are marked by an asterisk (P<. 05).
Percent change in triglycerides in baboons after the
injection of truncated apoC-I peptide intravenously is
shown in Figure 7. Except at day 4, plasma triglycerides182 Rampratap S. Kushwaha et al 2004:4 (2004)
decreased until day 19, after which they started to go up.
However, even after day 26, the triglyceride concentra-
tions were lower than at the baseline level. The values of
plasma triglycerides were lower than baseline values on
days 12, 15, 17, 19, and 23 (P<. 05).
IgGlevels,bodyweights,andfoodconsumption
T h ea v e r a g ev a l u e so fp l a s m aI g Gl e v e l si ne a c hb a -
boon in response to truncated apoC-I peptide infusion
did not change signiﬁcantly (individual values for each
baboon were 5.83 ± 0.09, 7.52 ± 0.12, and 6.57 ± 0.16,
mean±SE, n = 12). Similarly, there was no change in
either the body weights or food consumption (data not
shown).
Half-lifeofthetruncatedapoC-Ipeptide
intheplasma
The radioactivity was plotted as a percent of radioac-
tivity recovered at day 2. For calculation of the half-life of
the peptide, the decay of radioactivity was plotted from
day 30 to day 60. There was a log-linear decay of the
peptide radioactivity. On the basis of log-linear decay, the
half-life of the peptide was 14 days. The half-life of the
truncated apoC-I peptide was the same in both the sub-
cutaneous and the intravenous studies.
DISCUSSION
Our results demonstrate that the truncated apoC-I
peptide (human sequence) raises HDL cholesterol in two
species of nonhuman primates. The increase in HDL
cholesterol was preceded by a sharp and immediate de-
crease in VLDL + LDL cholesterol. There was no ad-
verse eﬀect on the immune response, body weight, or
food consumption of the baboons or cynomolgus mon-
keys. Thus, the peptide appears to be safe. The increase
in HDL cholesterol was accompanied by a decrease in
triglyceride concentration. The optimal dose of the pep-
tide was 10mg/kg body weight, and it had a long half-life
(14 days) in circulation.
Because the truncated apoC-I peptide is very hy-
drophobic, we used DMSO to dissolve it. This proce-
dure raises a question of whether any of the eﬀects on
lipid levels observed were mediated by the DMSO. We did
not inject DMSO into control animals. However, we used
diﬀerent amounts of DMSO in subcutaneous and intra-
venous experiments (0.075 versus 1.0mL), but did not
observe any diﬀerence in the eﬀect of large amounts of
DMSO on plasma lipid levels. Therefore, we concluded
that the observed eﬀects on lipid levels were due to the
truncated apoC-I peptide.
We have established that both synthetic and natural
(isolatedfrombaboonplasma)truncatedapoC-Ipeptides
act as an inhibitor of CETP [10]. Lipoproteins isolated
from animals infused with truncated apoC-I peptide have
decreased cholesteryl ester transfer from HDL to VLDL
+ LDL in presence of CETP. As presented in Figure 1,
the truncated peptide added in the plasma at 25µMs u b -
stantially inhibits cholesteryl ester from HDL to VLDL +
LDL. Since the transfer of cholesteryl ester from HDL to
VLDL + LDL in the plasma is mediated only by the CETP,
these results suggest that the truncated peptide inhibits
the CETP activity in the plasma.
Statins, which are strong inhibitors of 3-hydroxy-3-
methyl-CoAreductase,havebeenusedeﬀectivelytolower
VLDL + LDL cholesterol and reduce the risk of CHD in
high- (VLDL + LDL) subjects [15]. However, low levels of
HDL cholesterol are also associated with increased risk of
CHD [16]. Niacin is the only drug that has been shown
to raise HDL cholesterol eﬀectively [17], but the increase
in HDL cholesterol is minimal and the drug is often not
tolerated by subjects. Therefore, new drugs are needed to
safely raise HDL cholesterol levels.
A deﬁciency of CETP is associated with increased
HDL cholesterol levels and less atherosclerosis in human
subjects[18,19,20,21].InhibitingCETPactivityhasbeen
apotentialtargettoraiseHDLcholesterol[22,23],butthe
CETP target has been controversial because of conﬂicting
results from a number of studies in humans and animal
models [24, 25]. In some cases, decreased CETP was as-
sociated with increased risk of atherosclerosis. However,
the majority of studies suggest that deﬁciency of CETP
raises HDL and is antiatherogenic [26]. A recent study
suggests that human subjects with a mutation in CETP
(codon 405) had lower CETP activity, larger HDL and
LDL particles, and the phenotype was associated with
greater longevity and lower prevalence of hypertension,
cardiovascular disease, and the metabolic syndrome [27].
A number of CETP inhibitors have been described.
Some of these are synthetic compounds, whereas others
are naturally occurring components of plasma in hu-
mans and animals [10, 28, 29, 30, 31, 32, 33, 34].
These compounds inhibit CETP activity, thereby prevent-
ing cholesteryl ester from converting to apoB-containing
lipoproteins, which in turn increases the LDL receptor
activity [35]. A decrease in cholesteryl ester from HDL
to VLDL + LDL would increase HDL cholesterol that is
largerinsize[9,36].Theresultsofourpresentstudiesalso
show that the initial action of the CETP inhibitor peptide
in both species of nonhuman primates is that it leads to
a rapid decrease in the VLDL + LDL cholesterol, possi-
bly by increasing LDL receptor expression in the liver. The
increase in HDL cholesterol is slower but continues even
after the eﬀect of CETP inhibitor on the VLDL + LDL
cholesterol concentration has diminished.
Synthetic CETP inhibitors in animal models prevent
atherosclerosis [31, 37]. The present studies using trun-
catedapoC-Ipeptideinnonhumanprimatesdemonstrate
the beneﬁcial eﬀect of the CETP inhibitor peptide on
plasma lipoprotein proﬁle. However, these studies do not
show whether the peptide would prevent atherosclerosis
in humans or animals. Because the peptide occurs natu-
r a l l yi ns o m ef a m i l i e so fb a b o o n s ,w eh a v ec o m p a r e dt h e
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the truncated apoC-I peptide [38]. Baboons having the
truncated peptide had much less aortic lesions than ba-
boons without the truncated peptide even though they
had similar levels of plasma and VLDL + LDL cholesterol.
These observations suggest that the presence of the natu-
rally occurring peptide in the plasma of baboons prevents
atherosclerosis. Thus, the use of truncated peptide would
not only decrease VLDL + LDL and raise HDL, but would
also prevent the development of atherosclerosis.
Gene therapy with several genes in animal models
has prevented atherosclerosis. For example, VLDL + LDL
receptor-deﬁcient mice treated with helper-dependent
adenovirus containing apoA-I gene had higher plasma
HDL cholesterol and fewer arterial lesions as compared
withmicetreatedwithsalinealone[39].TheHDLinmice
with apoA-I gene transfer was also larger than the HDL
in mice treated with saline [39]. In addition to increas-
ing HDL, the CETP inhibitor also decreases VLDL + LDL
cholesterol. Therefore, the use of apoC-I truncated pep-
tide for gene therapy may be superior to that of apoA-I
to raise HDL and prevent atherosclerosis. These charac-
teristics of the apoC-I truncated peptide may make it an
ideal inhibitor of CETP to be used for treating hypoal-
phalipoproteinemic humans to raise HDL levels by infu-
sions or by gene therapy.
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